[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615123":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":30,"collaborators":10,"id":32,"slug":10,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":10,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patients with CLL",null,"no control group or comparator involved",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Research Site","RECRUITING","Minsk","Belarus",{"type":25,"coordinates":26},"Point",[27,28],27.56653,53.90019,{"lat":28,"lon":27},{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100615123",false,"NCT07288515","Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus","Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.","ALICIA(BY)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Confirmed diagnosis of CLL.\n* Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.\n* Treatment-naïve or R\u002FR CLL.\n* Ability and willingness to provide informed consent for study participation.\n\nExclusion Criteria:\n\n* Patients not satisfying any of the inclusion criteria.\n* Prior treatment with any BTK inhibitor.\n* Participation in other ongoing clinical trials.\n* Pregnant or breastfeeding females","ALL","18 Years",{"count":42,"type":43},50,"ESTIMATED","OBSERVATIONAL","to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL",[47],"Chronic Lymphocytic Leukemia",[49],"CLL","2026-06-12",{"date":52,"type":53},"2026-06-15","ACTUAL",{"date":55,"type":53},"2025-12-31",{"date":57,"type":43},"2029-12-31",{"name":5,"class":6},1]